The Metastatic Prostate Cancer (MPC) - Pipeline Insight, 2020 report provides comprehensive insights about 90+ companies and 110+ pipeline drugs in metastatic prostate cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
This report includes detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
There are approx. 90+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. Pre-registration phase include, Foresee Pharmaceuticals and Myovant Biosciences.
This report covers around 110+ products under different phases of clinical development like
Late stage products (Pre-registration and Phase III)
Mid-stage products (Phase II and Phase I/II) and
Early-stage products (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Mechanism of Action
Products have been categorized under various MOAs such as
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.